Family Health Study (Validation of a Family History of Cancer Questionnaire for Risk Factor Surveillance)
Status: | Completed |
---|---|
Conditions: | Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | September 2000 |
End Date: | July 2011 |
Family history of cancer is an important possible indicator of inherited cancer
susceptibility, which has helped identify individuals and families at high risk of inherited
cancers in research studies and clinical practice. While there are also various potential
uses of family history of cancer data in cancer surveillance, the completeness and accuracy
of family history of cancer data collected from the general population is unclear. In an
effort to evaluate the feasibility of conducting a national surveillance study to determine
the prevalence of family history of cancer in the U.S. population, the Risk Factor
Monitoring and Methods Branch will undertake a pilot study, entitled the Family Health
Study, that examines issues of data quality. In this study, a family history of cancer
questionnaire (FHCQ) will be developed for surveillance purposes and administered to a
random digit dial (RDD) sample of households in the state of Connecticut. Positive and
negative reports of common cancers in the respondent's families will be validated against
records of the Connecticut Tumor Registry (CTR) and other data sources.
The objectives are to: 1) assess the agreement between respondent reports of specific
cancers in first and second degree relatives and medical record-based reports, as measured
by percent concordance; 2) quantify the sensitivity, specificity and predictive value of the
FHCQ by cancer site; 3) evaluate the possible predictors of reporting accuracy, including
cancer site, year of diagnosis, kinship relation of the relative to the respondent and the
frequency and quality of their contact, overall family cohesiveness, respondent's own
history of cancer, and demographic factors; 4) describe the completeness and reliability of
family structure data.
Validation of selected relatives' cancer status will be done through data linkage to the
Connecticut Tumor Registry, other selected cancer registries, the National Death Index,
Medicare claims data bases, state death certificate registries, or by obtaining consent to
review available medical records from physicians and health care facilities. Self-reports of
respondents' cancer status will also be validated since this may be a predictor of ability
to accurately report family history. A pre-established tracing algorithm will be used to
triage cancer reports into the medical records systems where true cancer status is most
likely to be verified by the highest quality data. Validated cancer outco...
susceptibility, which has helped identify individuals and families at high risk of inherited
cancers in research studies and clinical practice. While there are also various potential
uses of family history of cancer data in cancer surveillance, the completeness and accuracy
of family history of cancer data collected from the general population is unclear. In an
effort to evaluate the feasibility of conducting a national surveillance study to determine
the prevalence of family history of cancer in the U.S. population, the Risk Factor
Monitoring and Methods Branch will undertake a pilot study, entitled the Family Health
Study, that examines issues of data quality. In this study, a family history of cancer
questionnaire (FHCQ) will be developed for surveillance purposes and administered to a
random digit dial (RDD) sample of households in the state of Connecticut. Positive and
negative reports of common cancers in the respondent's families will be validated against
records of the Connecticut Tumor Registry (CTR) and other data sources.
The objectives are to: 1) assess the agreement between respondent reports of specific
cancers in first and second degree relatives and medical record-based reports, as measured
by percent concordance; 2) quantify the sensitivity, specificity and predictive value of the
FHCQ by cancer site; 3) evaluate the possible predictors of reporting accuracy, including
cancer site, year of diagnosis, kinship relation of the relative to the respondent and the
frequency and quality of their contact, overall family cohesiveness, respondent's own
history of cancer, and demographic factors; 4) describe the completeness and reliability of
family structure data.
Validation of selected relatives' cancer status will be done through data linkage to the
Connecticut Tumor Registry, other selected cancer registries, the National Death Index,
Medicare claims data bases, state death certificate registries, or by obtaining consent to
review available medical records from physicians and health care facilities. Self-reports of
respondents' cancer status will also be validated since this may be a predictor of ability
to accurately report family history. A pre-established tracing algorithm will be used to
triage cancer reports into the medical records systems where true cancer status is most
likely to be verified by the highest quality data. Validated cancer outco...
Family history of cancer is an important possible indicator of inherited cancer
susceptibility, which has helped identify individuals and families at high risk of inherited
cancers in research studies and clinical practice. While there are also various potential
uses of family history of cancer data in cancer surveillance, the completeness and accuracy
of family history of cancer data collected from the general population is unclear. In an
effort to evaluate the feasibility of conducting a national surveillance study to determine
the prevalence of family history of cancer in the U.S. population, the Risk Factor
Monitoring and Methods Branch will undertake a pilot study, entitled the Family Health
Study, that examines issues of data quality. In this study, a family history of cancer
questionnaire (FHCQ) will be developed for surveillance purposes and administered to a
random digit dial (RDD) sample of households in the state of Connecticut. Positive and
negative reports of common cancers in the respondent's families will be validated against
records of the Connecticut Tumor Registry (CTR) and other data sources.
The objectives are to: 1) assess the agreement between respondent reports of specific
cancers in first and second degree relatives and medical record-based reports, as measured
by percent concordance; 2) quantify the sensitivity, specificity and predictive value of the
FHCQ by cancer site; 3) evaluate the possible predictors of reporting accuracy, including
cancer site, year of diagnosis, kinship relation of the relative to the respondent and the
frequency and quality of their contact, overall family cohesiveness, respondent's own
history of cancer, and demographic factors; 4) describe the completeness and reliability of
family structure data.
Validation of selected relatives' cancer status will be done through data linkage to the
Connecticut Tumor Registry, other selected cancer registries, the National Death Index,
Medicare claims data bases, state death certificate registries, or by obtaining consent to
review available medical records from physicians and health care facilities. Self-reports of
respondents' cancer status will also be validated since this may be a predictor of ability
to accurately report family history. A pre-established tracing algorithm will be used to
triage cancer reports into the medical records systems where true cancer status is most
likely to be verified by the highest quality data. Validated cancer outcomes will be
assigned ICD-9 codes by a nosology team following a double-blinded protocol. A certainty
level will be assigned to each cancer outcome based on the type of confirming medical
record, with evidence of microscopic confirmation of malignancy considered the most certain.
Statistical analyses to determine FHCQ1 sensitivity, specificity, and predictive value, will
be performed, accounting for level of certainty. Predictors of cancer reporting accuracy
will be examined using multivariate regression.
susceptibility, which has helped identify individuals and families at high risk of inherited
cancers in research studies and clinical practice. While there are also various potential
uses of family history of cancer data in cancer surveillance, the completeness and accuracy
of family history of cancer data collected from the general population is unclear. In an
effort to evaluate the feasibility of conducting a national surveillance study to determine
the prevalence of family history of cancer in the U.S. population, the Risk Factor
Monitoring and Methods Branch will undertake a pilot study, entitled the Family Health
Study, that examines issues of data quality. In this study, a family history of cancer
questionnaire (FHCQ) will be developed for surveillance purposes and administered to a
random digit dial (RDD) sample of households in the state of Connecticut. Positive and
negative reports of common cancers in the respondent's families will be validated against
records of the Connecticut Tumor Registry (CTR) and other data sources.
The objectives are to: 1) assess the agreement between respondent reports of specific
cancers in first and second degree relatives and medical record-based reports, as measured
by percent concordance; 2) quantify the sensitivity, specificity and predictive value of the
FHCQ by cancer site; 3) evaluate the possible predictors of reporting accuracy, including
cancer site, year of diagnosis, kinship relation of the relative to the respondent and the
frequency and quality of their contact, overall family cohesiveness, respondent's own
history of cancer, and demographic factors; 4) describe the completeness and reliability of
family structure data.
Validation of selected relatives' cancer status will be done through data linkage to the
Connecticut Tumor Registry, other selected cancer registries, the National Death Index,
Medicare claims data bases, state death certificate registries, or by obtaining consent to
review available medical records from physicians and health care facilities. Self-reports of
respondents' cancer status will also be validated since this may be a predictor of ability
to accurately report family history. A pre-established tracing algorithm will be used to
triage cancer reports into the medical records systems where true cancer status is most
likely to be verified by the highest quality data. Validated cancer outcomes will be
assigned ICD-9 codes by a nosology team following a double-blinded protocol. A certainty
level will be assigned to each cancer outcome based on the type of confirming medical
record, with evidence of microscopic confirmation of malignancy considered the most certain.
Statistical analyses to determine FHCQ1 sensitivity, specificity, and predictive value, will
be performed, accounting for level of certainty. Predictors of cancer reporting accuracy
will be examined using multivariate regression.
- INCLUSION CRITERIA:
Respondents recruited from a list-assisted random digit dial (RDD) sample of telephone
numbers from the state of Connecticut.
We found this trial at
1
site
9609 Medical Center Drive
Bethesda, Maryland 20892
Bethesda, Maryland 20892
1-800-422-6237

National Cancer Institute , 9000 Rockville Pike The National Cancer Institute (NCI) is part of...
Click here to add this to my saved trials
